Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

被引：0
作者：
Sabranski, Michael [1 ]
Wyen, Christoph [2 ]
Hoffmann, Christian [1 ]
Welz, Tanya [2 ]
Kolb, Michael [2 ]
Wolf, Eva [3 ]
Stellbrink, Hans-Juergen [1 ]
机构：
[1] ICH Study Ctr Hamburg, Infect Dis, Hamburg, Germany
[2] Praxis Ebertplatz, Infect Dis, Cologne, Germany
[3] MUC Res, Infect Dis, Munich, Germany
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2016年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
O214
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients
    Hoffmann, C.
    Welz, T.
    Sabranski, M.
    Kolb, M.
    Wolf, E.
    Stellbrink, H-J
    Wyen, C.
    HIV MEDICINE, 2017, 18 (01) : 56 - 63
  • [2] Dolutegravir discontinuation due to neuropsychiatric adverse events: A pharmacogenetic case-control study
    De Greef, J.
    Yombi, J. C.
    Vandercam, B.
    Vincent, A.
    Elens, L.
    Haufroid, V.
    Belkhir, L.
    HIV MEDICINE, 2023, 24 : 592 - 593
  • [3] Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir
    Bonfanti, Paolo
    Madeddu, Giordano
    Gulminetti, Roberto
    Squillace, Nicola
    Orofino, Giancarlo
    Vitiello, Paola
    Rusconi, Stefano
    Celesia, Benedetto M.
    Maggi, Paolo
    Ricci, Elena
    AIDS, 2017, 31 (03) : 455 - 457
  • [4] Dolutegravir and neuropsychiatric adverse events: a continuing debate
    Cailhol, Johann
    Rouyer, Cile
    Alloui, Chakib
    Jeantils, Vincent
    AIDS, 2017, 31 (14) : 2023 - 2024
  • [5] Pharmacogenetics of dolutegravir and bictegravir neuropsychiatric adverse events
    Hoffmann, Christian
    MacKay, Alice
    Schewe, Carl Knud
    Hansen, Stefan
    Buhk, Thomas
    Fenske, Stefan
    Stellbrink, Hans-Juergen
    Adam, Axel
    Sabranski, Michael
    Boffito, Marta
    Owen, Andrew
    Elliot, Emilie
    INFECTION, 2021, 49 (SUPPL 1) : S21 - S22
  • [6] Dolutegravir and Risk of Neuropsychiatric Adverse Events: A Pharmacogenetic Study
    De Greef, Julien
    Yombi, Jean Cyr
    Vincent, Anne
    Vandercam, Bernard
    de Timary, Philippe
    Boland, Lidvine
    Philippeau, Magali
    Panin, Nadtha
    Elens, Laure
    Haufroid, Vincent
    Belkhir, Leila
    JOURNAL OF INFECTIOUS DISEASES, 2025,
  • [7] Discontinuation of dolutegravir (DTG) containing therapy and adverse events in a Scottish cohort
    Cevik, M.
    Campbell, R.
    Raha, D.
    O'Shea, D.
    HIV MEDICINE, 2018, 19 : S76 - S76
  • [8] Dolutegravir Neuropsychiatric Adverse Events: Specific Drug Effect or Class Effect
    Yombi, Jean Cyr
    AIDS REVIEWS, 2018, 20 (01) : 13 - 25
  • [9] Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors
    Hoffmann, Christian
    Llibre, Josep M.
    AIDS REVIEWS, 2019, 21 (01) : 4 - 10
  • [10] Pharmacokinetic and pharmacogenetic associations with dolutegravir neuropsychiatric adverse events in an African population
    Griesel, Rulan
    Sinxadi, Phumla
    Kawuma, Aida
    Joska, John
    Sokhela, Simiso
    Akpomiemie, Godspower
    Venter, Francois
    Denti, Paolo
    Haas, David W.
    Maartens, Gary
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (11) : 3110 - 3117
12345